Xiaohai Chen
Overview
Explore the profile of Xiaohai Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen X, Hong F, Shen Y, Xia H, Shi L, Jiang Z, et al.
Biochem Pharmacol
. 2025 Mar;
236:116854.
PMID: 40054784
Tamoxifen, a selective estrogen receptor modulator (SERM) used in breast cancer therapy, requires metabolic activation by CYP3A4 to exert its biological effects. This study evaluated the effects of calcium channel...
2.
Chen D, Chen J, Xia H, Chen X, Hu J, Wu G, et al.
Front Pharmacol
. 2024 Dec;
15:1498339.
PMID: 39697549
Introduction: Sulfatinib is a novel oral tyrosine kinase inhibitor (TKI) with selective inhibition of fibroblast growth factor (FGFR), colony-stimulating factor 1 receptor (CSF-1R) and vascular endothelial growth factor receptor (VEGFR)...
3.
Zhang W, Xie M, Chen X, Ying Z, Bao Y, Gu Y, et al.
Aquat Toxicol
. 2024 Dec;
279:107202.
PMID: 39674103
Mercury (Hg) contamination is a major environmental concern that continuously impacts marine organisms, including the mangrove horseshoe crab (Carcinoscorpius rotundicauda). As a vulnerable species, C. rotundicauda holds significant ecological and...
4.
Chen X, Chen T, Xie Z, Xu L, Qi Z, Guo X
Oper Neurosurg (Hagerstown)
. 2024 Dec;
PMID: 39627172
Background And Objectives: In conventional freehand frontal ventriculostomy, the Kocher point is the entry point, the external auditory canal is the sagittal target, and the coronal targets include the ipsilateral...
5.
Chen D, Chen J, Shen Y, Chen X, Xia H, Liu Y, et al.
Pharm Biol
. 2024 Nov;
62(1):874-881.
PMID: 39540617
Context: Almonertinib is primarily metabolized by CYP3A4, so it could interact with a variety of drugs metabolized by CYP3A4, leading to the changes of systemic exposure. Objective: For the purpose...
6.
Xia H, Xu X, Chen J, Wu H, Shen Y, Chen X, et al.
Front Pharmacol
. 2024 Oct;
15:1495855.
PMID: 39399470
[This corrects the article DOI: 10.3389/fphar.2024.1403649.].
7.
Chen J, Hong F, Xia H, Shen Y, Chen X, Wu H, et al.
Chem Biol Interact
. 2024 Oct;
404:111265.
PMID: 39396719
Ponatinib is approved for use in patients with chronic myeloid leukemia (CML) who are resistant to or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. Given that ponatinib can induce...
8.
Li Q, Chen X, Zhang S, Li W, Lin H
Front Pharmacol
. 2024 Oct;
15:1470377.
PMID: 39359248
Riociguat, an orally soluble guanylate cyclase (sGC)-promoting drug, is mainly used in the clinical treatment of pulmonary hypertension (PH). In this study, a novel ultra-performance liquid chromatography-tandem mass spectrometry method...
9.
Xia H, Xu X, Chen J, Wu H, Shen Y, Chen X, et al.
Front Pharmacol
. 2024 Sep;
15:1403649.
PMID: 39329117
Ivacaftor is the first potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein approved for use alone in the treatment of cystic fibrosis (CF). Ivacaftor is primarily metabolized by...
10.
Hu J, Xia H, Chen X, Xu X, Wu H, Shen Y, et al.
BMC Cancer
. 2024 Sep;
24(1):1131.
PMID: 39261851
Background: Sunitinib, a newly developed multi-targeted tyrosine kinase inhibitor (TKI), has become a common therapeutic option for managing advanced renal cell carcinoma (RCC). Examining the mechanism underlying the interaction between...